Xilio Therapeutics, INC DEF 14A proxy statements

Xilio Therapeutics has filed its 2026 proxy statement, seeking stockholder approval for director elections, auditor ratification, and an amendment to its 2021 Stock Incentive Plan.

Xilio Therapeutics, Inc. will hold a special meeting on February 23, 2026, for stockholders to vote on a reverse stock split to meet Nasdaq's minimum bid price requirement.

Xilio Therapeutics will hold a special meeting on November 21, 2025, to vote on repricing underwater employee stock options and approving a new 2025 Stock Incentive Plan to address significant dilution and retain talent.

Xilio Therapeutics, a clinical-stage biotechnology company, announced the pricing of a $50.0 million underwritten public offering of pre-funded and common stock warrants to fund operations through Q3 2026.

Xilio Therapeutics is holding its 2025 Annual Meeting on June 10, 2025, seeking stockholder approval for key proposals including increasing authorized shares and officer exculpation.

Xilio Therapeutics is asking stockholders to approve increasing authorized common stock and providing officer exculpation at its 2025 annual meeting.

Xilio Therapeutics has scheduled its 2024 Annual Meeting for June 13, 2024, and is seeking stockholder votes on the election of directors and ratification of its independent accounting firm.

Xilio Therapeutics will hold its 2024 annual meeting of stockholders virtually on June 13, 2024, to vote on the election of directors and the ratification of the company's independent registered public accounting firm.